TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Urinary frequency and urgency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in anemia over time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: rate of early mortality
Endpoint domain: Mortality/survival
Primary endpoint: Reduction in dysmenorrhea pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: leg wound infection
Endpoint domain: Adverse events/effects
Primary endpoint: Change in ISNCSCI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in complete or partial occlusion of pre-glomerular arteries and arterioles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Changes in functional (and reversible) vasoconstriction of pre-glomerular arteries and arterioles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Changes in interstitial edema and cellular infiltration with tubulitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Changes in interstitial edema with tubular cell necrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Plasma Glucose Area Under the Curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Participants With a Diagnosis of ≥ CIN2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Functional outcome according to the Scandinavian Stroke Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in mean cells count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality of persons suffered an accident
Endpoint domain: Mortality/survival
Primary endpoint: Change in Health Related Quality of Life (HRQOL) as measured by the Short Form 36v2 (SF-36)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Health Related Quality of Life (HRQOL) as measured by the Disabilities of the Arm, Shoulder and Hand (DASH)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in HRQOL as measured by The EuroQol-5D-3L [EQ-5D]
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Feasibility of the modified life skills intervention
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Acceptability of the modified life skills intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants With Anaphylaxis
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Immune Complex-related Events
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of pressure injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Vaccinia-Specific Neutralizing Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percent Excess Weight Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Staging fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Number of Subjects With Adverse Events (AEs)/Serious AEs (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Objective Response [Complete Response (CR) + Partial Response (PR)] Rate at 16 Week Open-Label Period
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of Randomly Assigned Subjects Remaining Progression Free at 12 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Gastrointestinal Hormones
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Pancreatic Hormones
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Glucose and Free Fatty Acids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Self-report Physical Activity Levels
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Objective Physical Activity Levels
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Response Ratio (RRatio)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With All Adverse Events (AE) and Serious Adverse Events (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Hypoglycemia Episodes/Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline Vital Signs: Systolic and Diastolic Blood Pressure (SBP and DBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: response rate in overall skin disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Recurrence rate within 1 year after cabergoline withdrawal
Endpoint domain: Mortality/survival
Primary endpoint: Evaluate clinical outcomes associated with the use of therapeutic agents in children with JIA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evaluate clinical outcomes associated with the de-prescribing of therapeutic agents in children with JIA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evaluate the socioeconomic impact associated with the use of therapeutic agents in children with JIA
Endpoint domain: Resource use
Endpoint subdomain: Societal/carer burden
Primary endpoint: Percentage of Participants Who Complete the TMS Treatment
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Safety of 89Zr- DFO-SC16.56 PET/CT imaging
Endpoint domain: Adverse events/effects
Primary endpoint: Correlation between tumor uptake of 89Zr- DFO-SC16.56 with expression of DLL3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in physiological stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Depression Anxiety Stress Scale-21 (DASS-21) scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Subjective Units of Distress Scale (SUDS) scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Participation completion
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of hypertensive subjects with BP controlled
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of miturition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Time to miturition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Interincisor distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lateral jaw movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain derived neurotropic factor (BDNF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in hemostasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Total Symptom Burden
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change in Sleep Disturbance
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change in Sexual Function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Maximum Tolerated Dose (MTD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: VAP Occurrence
Endpoint domain: Adverse events/effects
Primary endpoint: Time to resolution of GI symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Parathormone level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: MV Coverage at 12 months of age
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Electrical Pain Threshold (EPT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Electrical Sensation Threshold (EST)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Sensitivity Testing changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Overall response (CR/PR) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Incidence of Post Transplant Lymphoproliferative Disorder (PTLD)
Endpoint domain: Adverse events/effects
Primary endpoint: Neurological Deficit by NIHSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Disability by mRS
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: immunogenicity - type I IFN
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: immunogenicity - response to KLH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: immunogenicity - T cells in DTH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Electrophysiological activity of the subthalamic nucleus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time to successfully complete the executive function test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C Reactive Protein Levels in mg/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence rates and severity of clinical adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mc Gill pain survey
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Roland Morris Disability index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: SF.36 Healthy life survey
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change From Baseline in Segmental Bioimpedance Measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: verbal memory and attention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: negative symptoms measured by the SANS total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tolerability and adverse effects
Endpoint domain: Adverse events/effects
Primary endpoint: Cross-sectional Area (CSA) of the Upper Airway
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Nocturia Episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change from Baseline in joint sense position (proprioception)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from Baseline in joint kinematics of reach
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change from Baseline in Electromyography during the reach
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Rate of device deficiencies
Endpoint domain: Adverse events/effects
Primary endpoint: Retention rate of recruited patients
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Achievement of full treatment dose of 120%rMT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Total score of diabetes symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Composite Memory Variable
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of hypoglycemic episodes below 54 mg/dl
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Accuracy of non-contrast MSCT chest in COVID-19
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Log 10 Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Level at Day 15
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Plasma Concentration (Cmax) for Telaprevir on Day 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Reach Maximum Plasma Concentration (Tmax) for Telaprevir on Day 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical response based on improvement of signs and symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in inhaled corticosteroids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total procedural Dose-area product (DAP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total DSA-related DAP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Image quality review
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TASC classification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in stroke volume index (SVI) >15%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Geometric Mean Titers (GMT) of Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Arterial methemoglobin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Insomnia Severity Index Score
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Identification of viral shedding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in blood pressure during dialysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Occurrence rate of AE/SAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Molecular pathway activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Visual analog scale (VAS) score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants with undiagnosed type 2 diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Antibody levels measured by ELISA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Quality of Life in Alzheimer's Disease
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Alzheimer's Disease Assessment Scale- Cognitive Subscale
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: response to DPPIV therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Pure-tone threshold change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rated Perceived Dyspnea (RPD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of patients with bleedings
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients with safety events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Patients With Objective Response (Complete Remission (CR) + Complete Remission With Incomplete Blood Count Recovery (CRi))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: real-time quantitative polymerase chain reaction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle Recovery Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes of condylar volume (mm3)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes of condylar head position
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time until diarrhea returns to level 0 or baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Proportion of 3/4 degree diarrhea in group A
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Oral neutrophils
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Matrix metalloproteinase-8 (MMP-8)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of the CT scans number
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Time to Resolution of Symptoms (AOM-SOS Score of 0 or 1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Resolution of Symptoms (AOM-SOS Score of 0 or 1 on Two Consecutive Occasions)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weighted Average Acute Otitis Media - Severity of Symptom (AOM-SOS Score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Walking mobility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: freedom from symptomatic AF, atrial tachycardia, and atrial flutter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Recovery of TOF ratio to 0.9 within 2 minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: poor disease outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: peer relationships/friendships
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Patient-reported overall daily pain intensity
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Global Satisfaction Subscale Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Hb Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Adverse side-effects
Endpoint domain: Adverse events/effects
Primary endpoint: Smoking abstinence/reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight and body mass index (BMI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: relative efficacy of olanzapine compared to clozapine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic value of microRNAs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: additional administration of analgesics
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: sensitivity and specificity of AI interpretation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain development
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Relapse-Free Response at 1 Year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Episodes of clinical worsening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in endometrial histopathology pattern
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change From Baseline to Day 95 in Active Forward Flexion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: HPV-16 and/or HPV-18 DNA negative conversion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Mu suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Ankle dorsiflexion Range of motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Adherence to daily inhaled COPD medications
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: cardiac iron concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Physiologic Pacing Implant Success Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pacing Capture Threshold for His Bundle Pacing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modified Borg Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Modified British Medical Research Council Dyspnea Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: COPD Assessment Test
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Beck Anxiety Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Potassium Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Long-term antibody kinetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of supraclavicular metastasis
Endpoint domain: Mortality/survival
Primary endpoint: Total KAP (Kerma-Air-Product)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Percentage of Doses Received
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: reduce risk of death
Endpoint domain: Mortality/survival
Primary endpoint: emergency room visits
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: admission to skilled nursing facility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative duration of drain placements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes